To determine the extent of neocortical involvement in multiple system atrophy (MSA), we used design-based stereological methods to estimate the total numbers of neurons, oligodendrocytes, astrocytes, and microglia in the frontal, parietal, temporal, and occipital cortex of brains from 11 patients with MSA and 11 age-and gender-matched control subjects. The stereological data were supported by cell marker expression analyses in tissue samples from the prefrontal cortex. We found significantly fewer neurons in the frontal and parietal cortex of MSA brains compared with control brains. Significantly more astrocytes and microglia were observed in the frontal, parietal, and temporal cortex of MSA brains, whereas no change in the total number of oligodendrocytes was seen in any of the neocortical regions. There were significantly fewer neurons in the frontal cortex of MSA patients with impaired executive function than in patients with normal executive function. Our results indicate that the involvement of the neocortex in MSA is far more widespread and substantial than previously thought. In addition, our results suggest that the increasingly recognized cognitive impairment in MSA may be related to neuronal loss in the frontal cortex.
Introduction
Multiple system atrophy (MSA) is a sporadic and rapidly progressing adult-onset neurodegenerative disorder that is clinically characterized by a variety of symptoms, including autonomic failure, Parkinsonism, cerebellar ataxia, and corticospinal dysfunction in any combination and with varying severity (Gilman et al. 2008) . Patients with MSA are clinically classified into one of the 2 subtypes (Parkinsonian or cerebellar) based on their predominant motor presentation (Gilman et al. 2008) . MSA is an important differential diagnosis for Parkinson's disease due to a considerable overlap between the clinical presentations (Wenning et al. 2000) .
The defining neuropathology in MSA is the deposition of insoluble alpha-synuclein-positive glial cytoplasmic inclusions (GCIs) located in oligodendrocytes together with the degeneration of striatonigral or olivopontocerebellar structures (Trojanowski and Revesz 2007) .
Although neocortical pathology in MSA is generally described as minimal (Inoue et al. 1997; Wenning et al. 1997; Ishizawa et al. 2004; Yoshida 2007; Ahmed et al. 2012) , several neuropathological studies also report cortical involvement in MSA (Jellinger 2014) . The most frequent cortical findings are GCIs, neuron loss, and gliosis in the motor and supplementary motor cortex (Papp et al. 1989; Papp and Lantos 1994; Konagaya et al. 1999 Konagaya et al. , 2002 Tsuchiya et al. 2000; Su et al. 2001; Wakabayashi and Takahashi 2006) . However, postcentral somatosensory cortex involvement and temporal lobe degeneration have also been reported (Armstrong et al. 2005; Mochizuki et al. 2008) . Furthermore, magnetic resonance imaging (MRI) studies demonstrate progressive cortical atrophy in patients with MSA (Horimoto et al. 2000; Konagaya et al. 2002; Brenneis et al. 2007; Minnerop et al. 2007; Chang et al. 2009; Kim et al. 2013) .
Stereology is a reliable method for the quantitative estimation of biological structures providing unbiased and precise estimates of structural features (Boyce et al. 2010; West 2012) . A major advantage of stereology is obtaining total quantities and stereology plays an important role in comparative studies of the human brain (Regeur et al. 1994; Pelvig et al. 2003 Pelvig et al. , 2008 Pedersen et al. 2005; Karlsen and Pakkenberg 2011; Fabricius et al. 2013) . We have previously estimated the total numbers of neurons and glial cells in the basal ganglia and red nucleus of patients with MSA using stereology. We found that microgliosis is a consistent and severe neuropathological feature of MSA, whereas no widespread and substantial loss of oligodendrocytes was observed. Further we demonstrated significant neuronal loss in the substantia nigra, striatum, and globus pallidus of patients with MSA, while neurons in other basal ganglia nuclei were spared (Salvesen et al. 2015) .
To determine the extent of neocortical involvement in MSA, we used stereology to quantify the total number of neocortical neurons and glial cells (oligodendrocytes, astrocytes, and microglia) in brains from 11 patients with MSA and 11 age-and gendermatched control subjects.
In addition, we employed a quantitative real-time polymerase chain reaction (qRT-PCR) approach to compare mRNA levels of specific markers for neurons, oligodendrocytes, astrocytes, and activated microglia measured in tissue samples from the prefrontal cortex of 10 MSA brains and 8 control brains.
Materials and Methods

Patients
Brains were obtained from autopsied individuals in compliance with Danish laws. Brain tissues from some of the control subjects have been included in previous studies (Karlsen and Pakkenberg 2011; Karlsen et al. 2014; Walloe et al. 2014) . The cause of death for 1 control subject was aortic aneurism, whereas the remaining 10 control subjects died from acute myocardial infarction. Demographic and autopsy-related data for the 2 groups are summarized in Table 1, and clinical characteristics for the patients with  MSA are listed in Table 2 . Clinical data were retrospectively obtained from patients' medical records. All patients were followed by a movement disorder specialist at the Movement Disorders Clinic, Department of Neurology, Bispebjerg University Hospital, Copenhagen, and received a probable diagnosis of MSA-P or MSA-C according to accepted clinical consensus criteria (Gilman et al. 2008 ). The cognitive status of the patients with MSA was assessed by a neuropsychologist specialized in movement disorders on average 3.3 years (range: 1-7 years) before death and 3.4 years (range: 1-8 years) after disease onset. The neuropsychological assessment was performed as a part of the diagnostic workup, and thus, the test battery was individually adjusted to the patient. Global cognitive impairment was tested with Mattis Dementia Rating Scale (n = 4) (cutoff 140/139) (Mattis 1976; Pirogovsky et al. 2014 ), Addenbrooke's Cognitive Examination (n = 1) (cutoff 86/85) (Stokholm et al. 2009 ), or mini-mental state examination (n = 4) (cutoff 24/25) (Folstein et al. 1975) . Impairment of executive function was assessed by the neuropsychologist using frontal assessment tests in different combinations including test of verbal fluency (s-words and animals) (n = 9), Stroop Color and Word Test (n = 8), Wisconsin Card Sorting Test (n = 7), and Lurias motor series (n = 5) (Dubois et al. 2000) . For 1 patient, details of frontal assessment tests and scores were not available; only the conclusion drawn by the neuropsychologist was included in the medical records. For 4 patients, only the conclusion of the global cognitive impairment test was available. MRI data were available for 10 patients; scans were performed on average 4 years before death (range: 2-5 years).
Tissue Processing
The protocol for tissue processing and stereological cell counting of whole hemispheres is previously described in detail (Karlsen and Pakkenberg 2011; Karlsen et al. 2014; Sigaard et al. 2014) . In short, the hemispheres were fixed for at least 5 months in 0.1 M sodium phosphate-buffered 4% formaldehyde ( pH 7.2). before being sliced into 3-cm-thick slabs starting from a random position within the first 3 cm. Each slab was embedded in paraffin using a Leica ASP300 S tissue processor (Leica, Wetzlar, Germany) followed by exhaustive coronal sectioning on a Leica SM2400 sliding microtome with a setting of 40 µm. A known and predetermined fraction of the sections were sampled and stained with Giemsa's azure eosin methylene blue solution (Merck, Darmstadt, Germany) and KHPO 4 at a 1:4 ratio.
Stereological Design
Sections were sampled according to the systematic uniform random sampling (Table 3) (Gundersen and Jensen 1987; Gundersen et al. 1999) .
The neocortex was defined as the four 6-layered cortical regions: the frontal, temporal, parietal, and occipital cortex. Before tissue processing, these 4 regions and the archicortex were delineated and painted on the pial surface in different colors for later identification (Braendgaard et al. 1990 ). Included in allocortex volume estimates were the hippocampus including the subiculum (archicortex), the pre-and parasubiculum, the entorhinal and perirhinal cortex, the retrosplenial area ( periarchicortex), the olfactory cortex and the piriform cortex ( paleocortex), and the cingulate gyrus (Zilles and Amunts 2012) . The basal ganglia, nucleus accumbens, thalamic nuclei, claustrum, and amygdala represented the subcortical gray matter. Volume estimates were obtained by using Cavalieri's principle (Gundersen and Jensen 1987) . Due to substantial tissue shrinkage when embedding in paraffin, volume estimates were multiplied by a shrinkage correction factor, V corr = V formalin /V paraffin (Uylings et al. 1986 ). To estimate V formalin , point counting was performed on images of tissue slabs from before processing. Control and MSA brains had a mean shrinkage of 36% and 35%, respectively, resulting in a V corr equal to approximately 1.6 for both groups.
Application of the shrinkage correction factor involves the assumption of uniform and concentric shrinkage of the entire hemisphere. However, differential shrinkage of brain tissue can never be excluded; therefore, volume estimates must be evaluated with this limitation.
The numerical densities of neurons and glial cells were estimated with the optical disector (Gundersen et al. 1988) . The neurons and glial cells were counted in systematically randomly placed counting frames, and the numerical density for each defined region was estimated. The total number of particles was calculated by multiplying the reference volume (uncorrected for shrinkage) with the numerical density. Multiplication by 2 was performed to obtain bilateral numbers. The counting was performed using a ×60 oil immersion objective resulting in final magnifications of ×2650. Sampling along the z-axis was performed with a disector height of 20 µm. The upper and lower guard zones were set at 5 and approximately 15 µm, respectively. The section thickness was measured in every disector to an average of 40 µm. No systematic variance in cell density was observed in the z-axis. All sections were coded during the stereological quantification process, and the investigator was blind to the disease status.
Cell Identification
Different cell types were identified by their morphology and spatial distribution (Pelvig et al. 2008) . Neurons have large nuclei 
Note: n, number; P/C, Parkinsonian/cerebellar subtype; MRI, magnetic resonance imaging; NA, not available. a Parkinsonism: +, bradykinesia or rigidity; ++, both.
b Cerebellar signs (gait ataxia, limb ataxia, cerebellar dysartria, and nystagmus): +, 1 or 2 positive signs; ++, 3 or 4 positive signs. c Autonomic failure: +, hypotension or urinary incontinence; ++, both.
d Pyramidal signs: +, Babinski sign or hyperreflexia.
e Wheelchair state = time from disease onset to wheelchair-bound state, *never reached a wheelchair-bound state.
f Positive red-flag categories: early instability, rapid progression, abnormal postures, bulbar dysfunction, respiratory dysfunction, and emotional incontinence. A category is positive if one or more symptoms within the category are present (Köllensperger et al. 2008 ). g The cognitive status was assessed by a neuropsychologist as a part of the diagnostic workup. Table 3 PCR primer pairs used for amplification of neuronal nuclei protein (NeuN), myelin basic protein (MBP), oligodendrocyte transcription factor 1 and 2 (OLIG1 and OLIG2), glial fibrillary acidic protein (GFAP), S100 calcium binding protein B (S100B), tumor necrosis factor alpha (TNF-α), interleukin 1 beta (IL-1β), CD14, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and β-actin Fig. 1a and b) . As the degenerative pathology of MSA may influence the morphology of cells, immunolabeling for astrocytes (anti-glial fibrillary acidic protein antibody, M0761, 1:100, DAKO, Glostrup, Denmark) and neurons (anti-NeuN antibody, MAB377, 1:1000, Millipore Billerica, MA, USA) in the striatum of control and MSA brains (Fig. 1c,d ), and immunolabeling of oligodendrocytes (anti-OLIG-2 antibody, AB9610, 1:500, Millipore, Germany) and microglia (anti-CD45RB antibody, 555 903, 1:100, BD Pharmingen, USA) in the white matter of the control and MSA brains were performed (Fig. 1e,f ) . All immunostainings were counterstained with hematoxylin. They corroborated the morphological criteria. Cells that could not be clearly identified as neurons or glial cells were classified separately; these cells made up <1% of the total cell counts in each region. Endothelial cells were not included in the cell counts.
Neuropathology
Tissue samples were taken from the substantia nigra, striatum, cerebral cortex, dentate nucleus, and cerebellar cortex of each brain. Tissue was embedded in paraffin, sliced into 8-µm-thick sections, and processed for immunohistochemistry with antibodies against alpha-synuclein (sc-12767, 1:9000, Santa Cruz Biotechnology, CA, USA) and ubiquitin (Z0458, 1:2000, DAKO) and counterstained with hematoxylin. Hematoxylin and eosin staining was also performed. Control brain sections were also processed for Klüver-Barrera staining and immunohistochemistry with antibodies against β-amyloid (M0872, 1:1000, DAKO) and τ (A0024, 1:1000, DAKO). Definite MSA diagnoses were confirmed by a pathologist based on the presence of GCIs, gliosis, and neuronal loss (Trojanowski and Revesz 2007) . In all of the MSA brains, GCIs were seen in the tissue samples from the substantia nigra and putamen but not in all of the cortical and cerebellar tissue samples (Fig. 1g) .
Quantitative Real-time Polymerase Chain Reaction
Tissue samples were collected from the prefrontal cortex of 6 of the included patients, another 4 patients with definite diagnosis of MSA, and 8 control subjects for qRT-PCR analysis of neuron and glial cell expression markers. The control group included tissue samples from 3 males and 5 females, with a mean age at death of 68.8 years (range: 43−81 years). The MSA group included tissue samples from 8 males and 2 females, with a mean age at death of 64 years (range: 54−74 years). Mean postmortem interval was 35.9 h (range: 12−80 h) for patients with MSA and 49.5 h (range: 22−115 h) for control subjects. The protocol for qRT-PCR is previously described in detail (Salvesen et al. 2015) . In short, the tissue samples were stored at −80°C prior to RNA extraction. RNA was extracted from 50 mg of frozen tissue using the GeneJET RNA Purification Kit (K0732 Thermo Fisher Scientific Inc., Waltham, MA, USA) according to the manufacturer's instructions. The RNA was eluted with 100 µL nuclease-free water and subjected to DNAse treatment using the Turbo DNA-free (AM1907 Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. RNA extraction was repeated for samples with RIN lower than 6. Only samples with RIN ≥6 were used for further analyses. The RNA samples were stored at −80°C until use. Sequences for each primer pair are given in Table 3 . A comparative cycle of threshold fluorescence method was used and the relative transcription levels of the target genes were normalized to that of GAPDH and β-actin, and expressed as relative quantity to the calibrator sample using the Pfaffl method (Pfaffl 2001) .
Statistics
The precision of estimates was expressed as coefficient of error (CE). An overview of CE values and numbers of neurons and glial cells are shown in Table 4 . Coefficient of variation (CV), equal to standard deviation divided by mean, which describes the interindividual variation for the group, is listed after the group means in Tables 5 and 6 . Sampling is considered optimal when CE is half or less than half of CV (Gundersen and Osterby 1981) . This was the case for all CE values listed in Table 4 except for that of astrocytes in the parietal cortex of MSA brains and MSA, multiple system atrophy; CE, coefficient of error. microglia in general. Thus, these estimated quantities must be evaluated considering this limitation. Data were analyzed using SigmaPlot 11.0 (Systat Software Inc., San Jose, CA, USA). Group differences in volumes, cell numbers, and cell densities were tested using Student's t-tests. In a few cases for which tests for normal distribution failed, Mann-Whitney U tests were used. Potential correlations were tested using the Pearson Product Moment Correlation Test. In the case of multiple pairwise correlations, significance level was adjusted using Bonferroni correction. Statistical analysis of mRNA levels was performed using Mann-Whitney U tests in Graphpad Prism software (Version 5, Graphpad Software Inc., La Jolla, CA, USA). Statistical significance was set at P < 0.05 (2-tailed).
Results
Data are reported as mean (CV). Total cell number estimates for the neocortical regions are shown in Table 5 and Figure 2 . Volume estimates corrected for shrinkage and cell density estimates are shown in Table 6 .
Clinical Data
Of the 11 patients, 3 were clinically classified as having MSA-C and 8 were classified as having MSA-P (Table 2 ). Due to the small number of MSA-C patients, no statistical comparisons were performed between the 2 disease subtypes. Seven patients exhibited pyramidal signs, and MRI showed cerebral cortical atrophy in 3 patients. Neuropsychological assessment revealed reduced executive function in 7 patients. No significant difference in the total numbers of neocortical neurons or glial cells between female brain and male brains was present in the MSA group (neurons: P = 0.09, glial cells: P = 0.58) or the control group (neurons: P = 0.80, glial cells: P = 0.76) or between right and left hemispheres in the MSA group (neurons: P = 0.10, glial cells: P = 0.84) or the control group (neurons: P = 0.70, glial cells: P = 0.69).
No correlation between total cell numbers and postmortem interval was seen in the MSA group (neurons: P = 0.45, glial cells: P = 0.79) or the control group (neurons: P = 0.95, glial cells: P = 0.71).
Neurons
The mean number of neocortical neurons was 13.7 × 10 9 (0.17) for MSA brains and 16.8 × 10 9 (0.11) for control brains.
There was no correlation between the number of neurons in the frontal or parietal cortex and the disease duration or severity (Table 2 ; expressed by years from disease onset to wheelchair-bound state and number of positive red-flag categories [Köllensperger et al. 2008] ).
There was no significant difference in the number of frontal cortex neurons between patients with and without pyramidal signs (P = 0.97; Table 2 ).
There were significantly fewer frontal cortex neurons in brains from patients with impaired executive function (mean = 3.6 × 10 9 ; range = 2.8 × 10 9 -4.8 × 10 9 ) than in brains from patients with normal executive function (mean = 4.6 × 10 9 ; range = 3.9 × 10 9 -5.2 × 10 9 ) (P = 0.04; Table 2 ).
Glial Cells
The mean number of neocortical glial cells was 24.5 × 10 9 (0.12)
for MSA brains and 21.9 × 10 9 (0.13) for control brains. In MSA Figure 2 . Total number of (a) neurons, (b) oligodendrocytes, (c) astrocytes, and (d) microglia in patients with MSA and control subjects in the 4 separate neocortical regions.
• = control brains (n = 11), ○ = MSA brains (n = 11). Horizontal bars indicate group means. P values are from Student's t-tests (*) or Mann-Whitney U tests (**). CS, control subjects; MSA, patients with multiple system atrophy.
brains, neocortical glial cells were composed of 58% oligodendrocytes, 38% astrocytes, and 4% microglia, whereas in control brains, the composition was 72% oligodendrocytes, 26% astrocytes, and 2% microglia. Global glia:neuron ratio was 1.8 (0.17) in MSA brains and 1.3 (0.13) in control brains with a significant difference between groups (P < 0.001).
After adjustment with Bonferroni correction, there were no significant correlations between numbers of neurons and astrocytes, numbers of neurons and microglia, or numbers of astrocytes and microglia in the frontal, temporal, or parietal cortex of MSA brains (data not shown).
Cell Marker mRNA Levels
Results of qRT-PCR analyses are shown in Figure 3 . Prefrontal cortex tissue samples from MSA brain had significantly lower levels of neuronal markers (NEFL: P = 0.004, NeuN: P = 0.004) and some oligodendroglia markers (MBP: P = 0.01, OLIG2: P = 0.01) compared with control brains (Fig. 3a,b) . In contrast, levels of astroglial markers (GFAP: P = 0.04, S100B: P = 0.04) and some activated microglial markers (TNF-α: P = 0.04, IL-1β: P = 0.002) were significantly higher in prefrontal cortex tissue samples from MSA brains compared with control brains (Fig. 3c,d ).
Discussion
To our knowledge, this is the first study to stereologically quantify the total numbers of neurons and glial cells in the neocortex of patients with MSA. The most important finding in our study was a substantial reduction in the number of neocortical neurons in patients with MSA. This result is consistent with findings of reduced cortical activity in previous imaging studies and may be important for understanding the clinical presentation of MSA and in searching for clinical markers of MSA diagnosis and progression (Brenneis et al. 2007; Minnerop et al. 2007; Chang et al. 2009 ). Specifically, we found fewer neurons in the frontal and parietal cortex and a trend toward fewer neurons in the temporal cortex of MSA patients compared with control subjects. Furthermore, we found more astrocytes and microglia in the frontal, parietal, and temporal cortex of MSA patients. Our finding that levels of TNF-α and IL-1β were elevated in prefrontal cortex tissue samples from patients with MSA points to disease-related changes in microglial activation and neuroinflammation. The significantly reduced neuron number, increased astrocyte and microglia numbers, and corresponding changes in levels of mRNA cell markers are consistent with previous reports of pathological changes in specific areas of the frontal cortex in patients with MSA (Papp et al. 1989; Papp and Lantos 1994; Konagaya et al. 1999 Konagaya et al. , 2002 Tsuchiya et al. 2000; Su et al. 2001; Armstrong et al. 2005; Wakabayashi and Takahashi 2006) . Furthermore, the topography of pathological changes observed here is similar to the previously described distribution of GCIs in the cerebral cortex and subcortical white matter (Papp and Lantos 1994; Inoue et al. 1997) .
The finding of significant neuron loss in the neocortex is surprisingly rare, with MSA being the first neurodegenerative disorder for which a widespread loss of neocortical neurons has been found. We previously reported normal neocortical neuron numbers in brains from individuals with Alzheimer's disease, Figure 3 . Semiquantitative RT-PCR analysis of neuronal (a) and glial cell (b, oligodendrocytes; c, astrocytes; d, activated microglia) markers in the prefrontal cortex of control (black bars, n = 8) and MSA (white bars, n = 10) brains. mRNA levels are normalized to mean mRNA levels of GAPDH and β-actin. Data represent mean ± SEM. P values are from Student's t-tests or Mann-Whitney U tests. CS, control subjects; MSA, patients with multiple system atrophy.
Parkinson's disease, amyotrophic lateral sclerosis, chronic alcoholism, and chronic schizophrenia as well as in brains from centenarians (Pakkenberg 1993; Regeur et al. 1994; Gredal et al. 2000; Pelvig et al. 2003; Pedersen et al. 2005; Fabricius et al. 2007 Fabricius et al. , 2013 . Neocortical neuron loss in MSA appears to be primarily due to changes in cell density and not cortical volume. This finding is in agreement with that of Spargo et al. (1996) , who in a nonstereological study found decreased neuronal density and increased glial density in motor and supplementary motor cortex in brains from patients with MSA compared with control subjects. Concurrent with a loss of neurons, we also found more glial cells in the MSA brains, which may explain the observation of normal neocortical volume. The global glia:neuron ratio was higher in MSA brains (1.8) than in control brains (1.3), but the extent to which this may influence cortical cytoarchitecture remains to be elucidated.
Pyramidal signs are important features of MSA, as they may help differentiate MSA from other neurodegenerative disorders, particularly Parkinson's disease (Gilman et al. 2008) . Neuron loss in the motor cortex may be correlated with pyramidal signs and secondary to demyelination of the pyramidal tract (Wenning et al. 1997; Tsuchiya et al. 2000; Halliday et al. 2011; Wenning and Krismer 2013) . We observed no difference in frontal cortex neuron number between MSA patients with and without pyramidal signs. However, no subdivision of the frontal cortex was performed for these subgroups; therefore, a clinicopathological relationship between pyramidal signs and neuron loss in specific regions or layers cannot be excluded.
Dementia is a non-supporting feature for diagnosis of MSA (Gilman et al. 2008) ; however, cognitive impairment in MSA may be more frequent than previously recognized. Brown et al. (2010) found that around 20% of MSA patients showed cognitive impairment primarily involving executive function. Whether cognitive impairment in MSA is caused by subcortical or cortical pathology is unclear (Halliday et al. 2011) , and in vivo imaging studies suggest both subcortical and frontal cortex involvement (Paviour et al. 2006; Kawai et al. 2008; Chang et al. 2009 ). We found fewer neurons in the frontal lobe of patients with MSA with executive dysfunction than those with no cognitive impairment, suggesting a relationship between executive dysfunction and frontal cortex neuron loss and supporting previous reports of a correlation between cognitive impairment and frontal lobe involvement in MSA (Kawai et al. 2008; Chang et al. 2009 ).
Whether the formation of GCIs leads to oligodendroglial cell death early in the disease or only causes oligodendroglial dysfunction is currently unknown (Yoshida 2007; Wenning et al. 2008; Ahmed et al. 2012) . We found no differences between MSA brains and control brains in the total numbers of oligodendrocytes despite significant decreases in frontal and parietal neuron numbers and increases in astrocyte and microglia numbers in the frontal, temporal, and parietal cortex of MSA brains. In agreement with our previous findings in the basal ganglia of MSA brains, this indicates that oligodendroglial cell loss may not be a widespread and substantial neuropathological feature of MSA. mRNA levels for some of the oligodendroglial markers were lower in the prefrontal cortex tissue samples from MSA brains compared with control brains, suggesting disease-related changes in the prefrontal cortex oligodendrocytes.
The main limitation of the present study is the small sample size, and our negative results must be interpreted with caution. Verification of our results in studies including larger sample sizes is needed. Cell quantification was performed using Giemsa-stained sections, and our results are therefore based on cell morphology alone. Astroglia-, oligodendroglia-, microglia-, and neuron-specific immunohistochemistry corroborated our cell identification criteria. However, not all astrocytes are stained by GFAP (Korzhevskii et al. 2005; Lyck et al. 2008) , and thus, a limitation of the present study is that identification of astrocytes that are not immunoreactive for GFAP has not been substantiated by immunohistochemistry. Microglial cells were primarily identified from the other cell types by their visibly smaller, darkly stained elongated or comma-shaped nuclei. Previous immunohistochemical studies have demonstrated varying shapes of microglial nuclei with different activity states (Lyck et al. 2008) . Therefore, we cannot exclude that our microglial cell numbers may be underestimated and must be evaluated considering this limitation.
In conclusion, we employed a robust stereological counting method to demonstrate significant changes in total cell numbers in the neocortex of patients with MSA, who had been followed by movement disorder specialists for years and were clinically and neuropathologically well characterized. Our results indicate that the involvement of the neocortex in MSA is far more widespread and substantial than previously thought and may be associated with the increasingly recognized cognitive impairment in MSA. These findings may have important clinical implications, such as helping distinguish MSA from Parkinson's disease, and may encourage further development of structural and functional neuroimaging techniques for MSA.
